Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26656005 | 1.00 | SLC1A1 (0.31) | SLC1A1 | |
| SCHEMBL16194713 | 0.80 | DNM1 (0.32) | — | |
| SCHEMBL2840047 | 0.80 | — | — | |
| SCHEMBL25291547 | 0.77 | ALDH1A1 (0.42) | — | |
| SCHEMBL27651567 | 0.77 | ALDH1A1 (0.42) | — | |
| SCHEMBL3306198 | 0.77 | ALDH1A1 (0.42) | — | |
| SCHEMBL5943150 | 0.77 | CERT1 (0.36) | — | |
| SCHEMBL22346865 | 0.76 | — | — | |
| SCHEMBL22346866 | 0.76 | — | — | |
| SCHEMBL16515196 | 0.76 | TRPA1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001889-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4514807-B1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250340570-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250340564-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250101034-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2025-03-27 | — | — | US | disclosed |
| EP-4522622-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220439-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001889-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SF3B1, SF3A1, SF3B5 | SLC1A1 2137/4885 |
| US-20250101034-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | RBM17, SNRPE, SNRPA1 | SLC1A1 4381/4885 |
| US-20250340570-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | RBM17, SF3A2, SMN1; SMN2 | SLC1A1 1991/4885 |
| US-20250340564-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | RBM17, SNRPE, SNRPA1 | SLC1A1 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.